NCT07396662 is a clinical trial of pancreatectomy in Pancreatic Neoplasm, sponsored by National Taiwan University Hospital.

Who is sponsoring NCT07396662?

NCT07396662 is sponsored by National Taiwan University Hospital.

What drugs are being tested in NCT07396662?

Interventions in NCT07396662: pancreatectomy.

What condition does NCT07396662 study?

NCT07396662 studies Pancreatic Neoplasm.

Is NCT07396662 still recruiting?

NCT07396662 is currently recruiting now. Last updated 9 February 2026.

Last reviewed 2026-02-09 · How we verify

NCT07396662

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endocrine-exocrine Functions and Prognosis After Pancreatectomy

Recruiting now Last updated 9 February 2026

What this trial tests

trial testing pancreatectomy in Pancreatic Neoplasm in 3,500 participants. Currently enrolling.

Timeline

1 January 2016

Primary endpoint
31 December 2034

31 December 2034

Quick facts

Lead sponsor	National Taiwan University Hospital
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	3,500
Start date	1 January 2016
Primary completion	31 December 2034
Estimated completion	31 December 2034
Sites	1 location across Taiwan

Drugs / interventions tested

pancreatectomy

Conditions studied

Pancreatic Neoplasm — all drugs for Pancreatic Neoplasm →

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 75, any sex, with Pancreatic Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pancreatic diseases often require surgery or invasive procedures to provide a chance for a cure. However, due to the pancreas's unique anatomical structure, its relative position to adjacent organs, and its dual endocrine and exocrine functions, the complexity of surgery is increased, impacting the patient's postoperative quality of life. Therefore, this project aims to retrospectively collect basic data, preoperative and postoperative blood tests (blood cell counts, biochemistry, tumor markers, glucose-related, lipid-related), and preoperative and postoperative imaging examinations (CT, MRI, Ultrasound, PET scan, Endoscopy, etc.) of patients who underwent pancreatic surgery at our hospital. We aim to compare whether surgical methods, lesion margin clearance rates, and postoperative remnant pancreatic volume affect the patient's endocrine function, exocrine function, quality of life, and disease prognosis. This analysis is intended to understand the indications, surgery-related factors, and prognosis for patients planning to undergo pancreatic surgery, with the expectation of providing more diverse and specific treatment recommendations for patients with pancreatic diseases in the future

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of pancreatectomy

Trials testing the same drug.

NCT06478056 — Correlation of Portal and Peripheral Venous ctDNA in Pancreatic Adenocarcinoma · NA · completed
NCT07405099 — Operative Risk After Pancreatic Surgery in Patients With End Stage Renal Disease · enrolling by invitation
NCT07382791 — Delayed Gastric Emptying After Pancreatic Surgery · recruiting
NCT05856474 — Management of Traumatic Pancreas Transection · recruiting

Other recruiting trials for Pancreatic Neoplasm

Currently open trials in the same condition.

NCT06807437 — Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula · Phase 3 · recruiting
NCT05687123 — Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors · Phase 1 · recruiting
NCT06122896 — Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals · EARLY_PHASE1 · recruiting
NCT06411795 — Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatodu · Phase 2 · recruiting
NCT05961982 — Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study · NA · recruiting

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07396662 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 9 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07396662.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing